GlaxoSmithKline scored a minor victory in the battle to keep sales of its $9 billion-a-year asthma treatment Advair from being lost to generic competitors.
from WSJ.com: US Business http://ift.tt/1jcaokD
via IFTTT
from WSJ.com: US Business http://ift.tt/1jcaokD
via IFTTT
No comments:
Post a Comment